Navigation Links
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Date:5/1/2012

MOUNTAIN VIEW, Calif., May 1, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May 2012:

Deutsche Bank 37th Annual Healthcare Conference
Tuesday, May 8, at 8:40 a.m. ET in Boston

Bank of America Merrill Lynch 2012 Healthcare Conference
Tuesday, May 15, at 3:40 p.m. PT in Las Vegas

A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following each presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the potential acute treatment of migraine. The U.S. Food and Drug Administration reviewed the New Drug Application for LEVADEX and on March 26, 2012, the Company received a Complete Response letter. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... ... of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food ... NBTX-001 Inhaler, allowing the Company to initiate its Phase 2b trial for the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... entrance into the Amazon Web Services (AWS) Public Sector Partner Program; a ... Public Sector Partner program recognizes and collaborates with partners that offer solutions ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... December 06, 2019 , ... Allegheny Health Network (AHN) has named ... joined AHN from WVU Medicine in May 2018, previously served as AHN’s Vice Chair ... interim chair since October and is also part of the pathology faculty at Drexel ...
(Date:12/6/2019)... ... December 06, 2019 , ... Dr. Scott Howell, a 2019 graduate of Trident ... the health benefits of coconut oil in the 7 November 2019 edition of ... Cardiometabolic Profile: A Structured Literature Review,” led by Dr. Hector O. Santos, examines the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... ranging from launching exceptional products that help people embrace, achieve, and maintain a ... “We’ve never been more committed to our mission of impacting world health, so ...
(Date:12/4/2019)... ... December 04, 2019 , ... Healthcare Real ... the only national awards dedicated to recognizing excellence in the areas of healthcare ... presented in nine different categories during the GlobeSt Healthcare Conference today in Scottsdale, ...
(Date:12/2/2019)... ... December 02, 2019 , ... TrialScope, the global leader ... the North American branch of the healthcare business of Merck KGaA, Darmstadt, Germany, ... educate and inform patients, caregivers, the public, patient advocacy groups and healthcare professionals ...
Breaking Medicine News(10 mins):